PerkinElmer completed the acquisition of BioLegend for $5.25bn.

PerkinElmer, a medical solutions provider, completed the acquisition of BioLegend, a global provider of life science antibodies and reagents, for $5.25bn. “We are thrilled to have the opportunity to bring our technologies and innovative cultures together to create seamless solutions to push science and discovery forward. We believe joining our teams presents an incredible opportunity to accelerate discoveries that help life science researchers leverage ever-developing technologies and novel approaches to better understand and fight disease," Prahlad Singh, PerkinElmer President and CEO.